VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today ...

Novo Nordisk A/S NVO and a privately-held biotechnology company, Aspect Biosystems, announced entering a collaboration, development, and license agreement. This will bring together Aspect’s ...

Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to ...

Novo Nordisk (NVO) (OTCPK:NONOF) signed a licensing agreement with Canada's Aspect Biosystems to develop bioprinted tissue therapies to replace, repair or supplement biological functions inside the ...

VANCOUVER, BC and NEW YORK, April 6, 2022 /PRNewswire/ -- Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is ...

An Aspect Biosystem scientist at work on a company bioprinter. (Aspect Photo) Vancouver, B.C.-based biotech company Aspect Biosystems inked a partnership worth potentially more than $2.6 billion with ...